# PR1 Vaccination in Myelodysplastic Syndrome (MDS)

> **NCT00893997** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** PR-1 vaccine

## Key facts

- **NCT ID:** NCT00893997
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The trial was ended per sponsor due to slow accrual rates.
- **Last updated:** 2012-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00893997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00893997, "PR1 Vaccination in Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00893997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*